|
|
|
| Effect of Fuzheng Jiedu Decoction and dumai moxibustion in the treatment of non small cell lung cancer patients in the late stage of lung and spleen deficiency syndrome and the level of immune inflammation |
| HUANG Kaihong1 WANG Yajun1 LIAN Jianfeng2 DAI Qijun3▲ |
1.Department of Oncology, Haian Clinical College, Yangzhou University Medical School, Jiangsu Province, Haian 226600, China;
2.Department of Acupuncture, Haian Clinical College, Yangzhou University Medical School, Jiangsu Province, Haian 226600, China;
3.Department of Internal Medicine, Haian Clinical College, Yangzhou University Medical School,Jiangsu Province, Haian 226600, China
|
|
|
|
Abstract Objective To explore the effect of Fuzheng Jiedu Decoction combined with dumai moxibustion in the treatment of non-small cell lung cancer patients in the stage of lung and spleen deficiency syndrome. Methods From January 2020 to January 2022, 82 patients with advanced non-small cell lung cancer admitted to were divided into two groups by random number table method, with 41 cases in each group. The control group was treated with Paclitaxel+Carboplatin, and the study group was treated with dumai moxibustion and Fuzheng Jiedu Decoction on the basis of the control group. After two months of treatment, the scores of traditional Chinese medicine syndromes, levels of immune inflammatory factors (interleukin-6 [IL-6], immunoglobulin A [IgA]) and adverse reactions of the two groups were compared. Results Before treatment, there were no significant differences between the two groups in main syndrome score, secondary syndrome score, IL-6, and IgA (P＞0.05). After treatment, the main syndrome score, secondary syndrome score and IL-6 of the two groups decreased, and the study group was lower than the control group, with a statistically significant difference (P＜0.05). The levels of IgA in the two groups were higher compared with before treatment, and the study group was higher than the control group (P＜0.05). The clinical effect in the study group was better than that in the control group, with a statistically significant difference (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion Fuzheng Jiedu Decoction combined with dumai moxibustion in the treatment of advanced non-small cell lung cancer is more helpful for the patients to regulate the expression of immune inflammatory factors, and the clinical effect is superior.
|
|
|
|
|
|
[1] 迟文成，牛泽基，姜家康，等.六君子汤加味治疗非小细胞肺癌化疗后白细胞减少症的有效性分析[J].中医药学报，2022，50（5）：76-79.
[2] 高海利，吴晋芳，陈尧，等.下气汤对中晚期非小细胞肺癌癌因性疲乏的防治作用研究[J].广州中医药大学学报，2022，39（4）：769-775.
[3] 王恺晨，柳正植，彭煜，等.参赭镇气汤联合顺铂和培美曲塞对晚期非小细胞肺癌患者的临床疗效[J].中成药，2022，44（3）：785-789.
[4] 张梦馨，祝云鹤，白月琴，等.培元抗癌汤联合NP化疗方案治疗晚期非小细胞肺癌疗效及对血清肿瘤标志物和免疫功能的影响[J].现代中西医结合杂志，2022，31（15）：2108-2111，2116.
[5] 郭宇轩，曾柏荣，王理槐.《医宗必读》攻补兼施法对肿瘤证治的贡献[J].河北中医，2021，43（1）：147-150.
[6] 张春雷，李贵新，宋鹏，等.扶正解毒汤辅助克唑替尼对晚期非小细胞肺癌患者血清Pokemon及AGR2表达的影响[J].广州中医药大学学报，2022，39（2）：234-240.
[7] 张永强，刘梅，罗梓桓.小青龙汤联合督脉灸治疗痰湿内蕴型肺癌咳嗽疗效及对疼痛、炎症反应、生活质量的影响[J].现代中西医结合杂志，2022，31（5）：613-618，721.
[8] 陈芳海.山西中医[J].山西中医杂志，1994，10（8）：23.
[9] 中华医学会，中华医学会肿瘤学分会，中华医学会杂志社.中华医学会肺癌临床诊疗指南（2019版）[J].中华肿瘤杂志，2020，42（4）：257-287.
[10] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：216-221.
[11] 王晓彤，王欣欣，李妍，等.中医康复技术操作规范·督灸[J].康复学报，2020，30（4）：266-268.
[12] 郭晓黎，任小宁，樊一波，等.沙参麦冬汤通过调节EGFR/ MEK/ERK信号通路对非小细胞肺癌细胞增殖、凋亡和自噬的影响[J].中国药师，2022，25（10）：1707-1713.
[13] 王理槐，孙银辉，张领兄，等.血府逐瘀汤对非小细胞肺癌荷瘤小鼠GSK-3β与β-catenin表达的影响[J].现代中西医结合杂志，2022，31（5）：603-607.
[14] 陈艳，孙连庆，胡粒山.六君子汤加减对晚期非小细胞肺癌GP方案肺脾气虚型患者的作用机制研究[J].西部中医药，2022，35（1）：119-123.
[15] 刘志勇，韩圣宾，郭丽纳，等.补肺化瘀汤辅助GP方案化疗对非小细胞肺癌患者T淋巴细胞亚群水平及毒副反应的影响[J].贵州医药，2022，46（4）：518-519.
[16] 朱世航，胡彦辉.扶正祛痰解毒汤联合吉非替尼片治疗气虚痰瘀型非小细胞肺癌临床研究[J].新中医，2022， 54（11）：198-201.
[17] 梁元钰，吕晓东，庞立健，等.基于《素问·咳论》的咳类疾病诊疗网络构建[J].世界中医药，2021，16（14）：2183- 2188.
[18] 李丹，张亚密，王征，等.从五脏六腑论治肺癌咳嗽[J].辽宁中医杂志，2021，48（10）：63-66.
[19] 刘丽婷，李杰，吴童，等.从“治未病·既病防变——培土生金法”论《金匮要略·肺萎》篇中组方思路[J].天津中医药，2019，36（6）：572-574.
[20] 王晶，刘惠娟，欧阳里知，等.《灵枢》“针所不为，灸之所宜”之浅析[J].辽宁中医杂志，2021，48（1）：81-82.
[21] 覃祥龙，吕婷婷，韦媛菊，等.基于网络药理学探讨加减补肺化瘀汤治疗非小细胞肺癌的作用机制[J].广西医学，2022，44（3）：296-302.
[22] 许英，杨洁，李娜，等.特罗凯靶向治疗联合培美曲塞和顺铂对非小细胞肺癌患者血清肿瘤标志物、免疫球蛋白和T淋巴细胞亚群的影响[J].现代生物医学进展，2021，21（17）：3264-3267，3335.
[23] 柴长斌，马茜，周丽，等.黄芪多糖可提升小鼠巨噬细胞和自然杀伤细胞的抗肿瘤作用[J].中华微生物学和免疫学杂志，2019，39（4）：292-297.
[24] 董雅倩，张佳幸，龚琳娜，等.白花蛇舌草环烯醚萜的鉴定及基于网络药理学的抗肾纤维化作用的机制研究[J].药学学报，2020，55（12）：2934-2941.
[25] 周春红，许霓珊，曹惠慧，等.白花蛇舌草抗肝癌作用[J].中国药理学与毒理学杂志，2021，35（10）：757-758. |
|
|
|
